Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MDH2 | P40926 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239247 | 0.90 | DPP4 (0.42) | DPP4EDNRAHRH3LTB4RLTB4R2 | |
| SCHEMBL5233462 | 0.87 | PLA2G2D (0.41) | EDNRAMAPK8ALDH1A1HPGDMDH2 | |
| SCHEMBL5234425 | 0.86 | DPP4 (0.47) | DPP4EDNRAHRH3SMN1; SMN2MAOB | |
| SCHEMBL27599395 | 0.86 | DPP4 (0.48) | DPP4EDNRAHRH3ALDH1A1HPGD | |
| SCHEMBL5239136 | 0.86 | MAPK8 (0.42) | EDNRAHRH3MAPK8ALDH1A1HPGD | |
| SCHEMBL5236115 | 0.85 | DPP4 (0.43) | DPP4EDNRAHRH3LTB4RLTB4R2 | |
| SCHEMBL5237284 | 0.84 | DPP4 (0.46) | DPP4HRH3SMN1; SMN2MAOB | |
| SCHEMBL5236109 | 0.84 | DPP4 (0.46) | DPP4EDNRAMAOB | |
| SCHEMBL5234388 | 0.84 | DPP4 (0.58) | DPP4EDNRAMAPK8 | |
| SCHEMBL5576568 | 0.84 | DPP4 (0.48) | DPP4EDNRAHRH3ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| CN-1500080-A | Fused heterocyclic compounds | ����ҩƷ��ҵ��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2002062764-A9 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885EDNRA 948/4885HRH3 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.